Second-line chemotherapie after platinum or platinum and paclitaxel- based chemotherapy for ovarian cancer: A systematic review;2nd-line-chemotherapie nach platin- oder platin-paclitaxel-haltiger primartherapie beim ovarialkarzinom: Eine systematische ubersicht der publizierten daten bis 1998

Geburtshilfe und Frauenheilkunde

Volumn 60, Issue 1, 2000, Pages 41-58

  Du Bois, Andreas ^a   Luck H J ^b   Bauknecht, T ^b   Pfisterer, J ^b   Meier, W ^b  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b Dr Horst Schmidt Kliniken ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN DERIVATIVE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; TOPOTECAN; TREOSULFAN;

ADVANCED CANCER; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; OVARY CANCER; SURVIVAL;

EID: 17544395243     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9764     Document Type: Article

References (243)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. J Engl J Med 1996; 334: 1-6
2. Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows highly significant improved overall survival (OS) for cisplatinpaclitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NICIC-CTG and Scottish intergroup trial. Proc Am Soc Clin Oncol 1998; 17: 1394
3. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992; 10: 513-514
4. du Bois A, Lück HJ, Meerpohl HG. Rezidiv-und 2nd-line Therapien beim Ovarialkarzinom: eine Übersicht konventioneller systemischer Therapiemodalitäten. Zentrbl Gynäkol 1997; 119: 299-323
5. Kavanagh JJ, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-1588
6. Ozols RF, Ostchega Y, Curt C, Young RC. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987; 5: 197-201
7. Colombo N, Speyer JL, Green M et al. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol 1989; 23: 323-328
8. Williams LL, Fudge M, Burnett LS, Jones HW. Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin. Am J Clin Oncol 1992; 15: 331-336
9. Eisenhauer EA, Swenerton KD, Sturgeon FG, Fine S, O'Reilly SE. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Trials Group study. Cancer Treat Rep 1986; 70: 1195-1198
10. Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA, Calvert AH. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60: 767-769
11. Repetto L, Chiara S, Mammoliti S et al. Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecol Oncol 1990; 39: 146-149
12. Piver MS, Barlow JJ, Lele SB, Malfetano JH, McPhee ME. Cis-diamminedichloroplatinum (II): second-line induction chemotherapy in advanced ovarian adenocarcinoma. J Surg Oncol 1983; 24:329-331
13. Scotto V, Sbiroli C. Weekly cis-platin as third line chemotherapy in advanced ovarian carcinoma. Phase II study. Eur J Gynaec Oncol 1991; 12: 51-53
14. Chambers SK, Davis CA, Schwartz PE, Kohorn EI, Chambers JT. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study. Clin Cancer Res 1996; 2: 1693-1697
15. Kjorstad K, Harris A, Bertelsen K et al. A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol 1992; 3:217-222
16. Pohl J, Meerpohl HG, Pfleiderer A. Phase II trial of carboplatin in advanced ovarian cancer. Cancer Res Clin Oncol 1988; 114: S53
17. Hoskins PJ, O'Reilly SE, Swenerton KD. The "failure free interval" defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing, Int J Gynecol Cancer 1991; 1: 205-208
18. Calvert AH, Harland SJ, Newell DR. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9: 140-147
19. Manetto A, Blessing JA, Hurteau JA. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 1998; 68: 45-46
20. Chambers SK, Davis CA, Chambers JT, Schwartz PE, Lorber MT, Handschumacher RE. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Clin Cancer Res 1996; 2: 1699-1704
21. Kavanagh JJ, Edwards CL, Freedman RS et al. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol Oncol 1995; 58: 106-109
22. Gietema JA, Veldhuis GJ, Guchelaar HJ et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 1995; 71: 1302-1307
23. Markman M, De Marco LC, Birkhofer M et al. Phase II trial of zeniplatin (CL-286 588), a new platinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. J Cancer Res Clin Oncol 1993; 119: 234-236
24. Sessa C, Vermorken J, Renard J et al. Phase II study of iproplatin in advanced ovarian carcinoma. J Clin Oncol 1988; 6: 98-105
25. Weiss G, Green S, Alberts DS et al. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. Eur J Cancer 1991; 27: 135-138
26. Roberts JA, Kudelka AP, Spriggs DR et al. A phase 2 study of cisplatin analog CI-973 in the treatment of patients with refractory, advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 257-260
27. Chollet P, Bensmaine MA, Brienza S et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-1070
28. Dieras V, Bounnoux P, Petit T et al. Oxaliplatin (L-OHP) phase II study in platinum (PT) pretreated advanced ovarian cancer (AOC): preliminary results. Proc Am Soc Clin Oncol 1998; 17: 364A
29. Soulie P, Bensmaine A, Garrino C et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 1997; 33: 1400-1406
30. Piccart-Gebhart M, Green J, Lacave A et al. Oxaliplatin (L-OHP) phase 11 study platinum (Pt) pretreated advanced ovarian cancer (AOC): preliminary results. Proc Am Soc Clin Oncol 1998; 17: 1405
31. Kavanagh JJ, Kudelka AP, Gonzales de Leon C et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996; 2: 837-842
32. Aapro M, Pujade-Lauraine E, Lhomme C et al. EORTC Clinical Screening Group phase II study of taxotere in ovarian cancer. Ann Oncol 1994; 5: 202
33. Francis P, Schneider J, Hann L et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12: 2301-2308
34. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer 1997; 33: 2167-2170
35. Seewaldt VL, Greer BE, Cain JM et al. Paclitaxel (taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 1994; 170:1666-1671
36. Trimple EL, Adams JD, Vena D et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-2410
37. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666
38. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748-1753
39. Sarosy G, Stone DA, Rothenberg M et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992: 10: 1165-1170
40. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989; 111: 273-279
41. Gore ME, Levy V, Rustin G et al. Paclitaxel (taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016-1019
42. Sweeten KM, Gershenson DM, Burke TW, Morris M, Levenback C, Silva EG. Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TTC). Gynecol Oncol 1995; 59: 211-215
43. Athanassiou A, Pectasides D, Varthalitis I, Dimitriades M, Tsiliakos S, Papazachariou A. Taxol patients with cis/carboplatin-refractory ovarian carcinoma. Proc Am Soc Clin Oncol 1994; 13: 271
44. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193
45. du Bois A, Lueck HJ, Buser K et al. Extended phase II study of paclitaxel as 3 hour infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 1997; 33: 379-384
46. Markman M, Rose P, Kennedy A et al. A phase II study of 96 hour paclitaxel (P) as salvage therapy in ovarian carcinoma (OC). Proc Am Soc Clin Oncol 1996; 15: 283
47. Colombo N, Marzola M, Parma G et al. Paclitaxel vs. CAP (cyclophosphamide; adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study. Proc Am Soc Clin Oncol 1996; 15:279
48. Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol 1996; 64: 109-113
49. Tresukol D, Kudelka AP, Gonzales de Leon C et al. Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer. Eur J Gynaec Oncol 1996; 17: 188-191
50. Bruzzone M, Catsafados E, Miglietta L et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology 1996; 53: 349-353
51. Andersson H, Horvath G, Mellqvist L, Westberg R et al. Taxol given weekly in advanced previously treated ovarian carcinomas - a pilot study. Int J Gynecol Cancer 1997; 7: 262-266
52. Fields A, Hochster H, Runowicz C et al. SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: a phase II trial with renewed responses. Proc Am Soc Clin Oncol 1997; 16: 351A
53. Soulie P, Trandafir L, Taama A et al. Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Anti-Cancer Drugs 1997; 8: 763-766
54. Kuehnle H, Lenaz L, Meerpohl HG et al. Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol 1988; 7: 527
55. Markman M, Hakes T, Reichman B et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992; 119: 55-57
56. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60-63
57. Kavanagh JJ, Tresukosol D, De Leon CG et al. Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer 1995; 5: 351-354
58. de Wit R, van der Burg MEL, v. d. Gaast A, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5: 656-657
59. Rose PG, Blessing JA, Mayer AR, Homesly HD. Prolonged oral etoposide as second line therapy for platinum resistant (platr) and platinum sensitive (plats) ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 1996; 15: 282
60. Naumann RW, Alvarez RD, Segars ET et al. A phase II study of high-dose etoposide as a second-line therapy in patients with epithelial ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: 364A
61. Kuhn W, Schmalfeldt B, Pache L et al. Disease-adapted relapse therapy for ovarian cancer: results of a prospective study, Int J Oncol 1998; 13: 57-63
62. Armstrong D, Rowinsky E, Donehower R, Rosenshein N, Walczak J, McGuire W. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275
63. Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-656
64. Kudelka AP, Tresukosal D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-1557
65. Gordon A, Bookman M, Malmstrom H et al. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 1996; 15: 282
66. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056-3061
67. Hochster H, Speyer J, Wadler S et al. Phase II study of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer: a highly active regimen, (a NYGOG study). Proc Am Soc Clin Oncol 1996; 15:285
68. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66: 349
69. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998; 16:2233-2237
70. Bookman MA, Malmström H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-3352
71. National Institutes of Health Consensus Developement Conference Statement. Ovarian Cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55: S4-S14
72. Schwartz PE, Keating G, Kohorn EI, Chambers JT. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy. Gynecol Oncol 1986; 25: 340-346
73. Fanning J, Hilgers RD, Hutson E. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer. Am J Clin Oncol 1994; 17: 335-337
74. Lorusso V, Catino A, Leone B et al. Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 1993; 11: 1952-1956
75. Lele SB, Piver MS, Malfetano J. Cisplatin plus VP16-213 in refractory ovarian carcinoma. Am J Clin Oncol 1987; 10: 21-22
76. Baker TR, Piver MS, Hempling RE. The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma. Eur J Gynaec Oncol 1993; 14: 18-22
77. Menczer J, Ben-Baruch G, Rizel S, Brenner H. Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. Eur J Gynaec Oncol 1992; 13: 316-318
78. Ahmed FY, King DM, Nicol B et al. Preliminary results of infusional chemotherapy (cisplatin, epirubicin and 5-fluorouracil, ECF) for refractory and relapsed epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14:280
79. ten Bokkel Huinink WW, Dalesio O, Rodenhuis. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at the Netherlands Cancer Institute. Sem Oncol 1992: 19: 99-101
80. Beddoe AM, Dottino PR, Cohen CJ. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma. Mt Sinai J Med 1993; 60: 311-316
81. Dobbs SP, Gribbin C, Chan SY, Bessel EM. Second-line treatment with ifosfamide and carboplatin in patients with ovarian carcinoma relapsing after treatment with carboplatin. Eur J Cancer 1994; 30A: 30-33
82. De Lena M, Lorusso V, Bottalico C. Revertant and potentiating activity of lonidamin in patients with ovarian cancer previously treated with platinum. J Clin Oncol 1997; 15: 3208-3213
83. van der Burg MEL, Logmans A, de Wit R et al. Six weeks of weekly high-dose cisplatin (P) and daily oral vepesid (VP): a highly active regimen for ovarian cancer patients (PTS) failing on or relapsing after conventional platinum containing combination chemotherapy. Proc Am Soc Clin Oncol 1996; 15: 285
84. Bower M, Goodchild K, Evans H, Nelstdorf A, Rustin GJS. FaFEC: a novel regimen for advanced ovarian cancer, Int J Gynecol Cancer 1997; 7: 14-17
85. Johnston CM, Pearl ML, Reynolds RK, Roberts JA, Morley GW. Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel. Eur J Gynaec Oncol 1995; 16: 439-447
86. Goldberg JM, Piver MS, Hempling RH, Recio FO. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996; 63: 312-317
87. Guastalla JP, Pujade-Lauraine E, Orfeuvre H et al. Efficacy and safety of carboplatin (Cb)-paclitaxel (Px) association in pretreated advanced ovarian cancer (AOC) patients (pts). Proc Am Soc Clin Oncol 1996; 15: 278
88. Kosmas C, Polyzos A, Tsavaris N et al. Outpatient, taxol (T) ifosfamide (I) and cisplatin (C) (TIP) as salvage chemotherapy in pretreated patients with ovarian cancer (O.C.). Proc Am Soc Clin Oncol 1998; 17: 366A
89. Guastalla JP, Pujade-Lauraine E, Weber B et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. Ann Oncol 1998; 9: 37-43
90. Sugiyama T, Yakushiji M, Nishida T et al. Irinotecan (CPT-11) combined with cisplatin on patients with refractory or recurrent ovarian cancer. Cancer Letters 1998; 128: 211-218
91. Baekelandt M, Covelli A, Trope C, Kristensen G. Phase I/II trial of cisplatin and doxorubicin with SDZ PSC 833 in patients with refractory ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: 757
92. Bruckner HW, Cagnoni PJ, Lee JM, Chesser MR, Andreotti PE. A sequence of adriamycin and taxol infusions for refractory ovarian cancer. Proc Am Soc Clin Oncol 1994; 13: 271
93. Behrens B, Copeland L, Balcerzak S, Staubus A, Vandre D, Villasmil P. A phase I taxol (T)/altretamine (A) doublet clinical trial in women with refractory ovarian cancer (OC). NCI #T92-0014. Proc Am Soc Clin Oncol 1994; 13: 271
94. Santoro A, Maiorino L, Santoro M. Taxol (T) plus doxorubicin (D) in platinum (P) pretreated advanced ovarian cancer (A.O.C.) patients (PTS). Proc Am Soc Clin Oncol 1996; 15: 288
95. Klaassen U, Harstrick A, Stahl M et al. Paclitaxel and ifosfamide in pretreated patients with advanced ovarian carcinoma - results of a phase I/II study. Proc Am Soc Clin Oncol 1996; 15: 295
96. Dimopoulos MA, Papadimitriou C, Gennatas C et al. Ifosfamide and paclitaxel salvage chemotherapie for advanced epithelial ovarian cancer. Ann Oncol 1997; 8: 195-197
97. Kurbacher CM, Bruckner HW, Cree IA et al. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 1997; 3: 1527-1533
98. Trope C, Kaern J, Hogberg T. A phase II study of paclitaxel and doxorubicin as second-line treatment in recurrent ovarian cancer after cisplatin failure. Gynecol Oncol 1998; 68: 123
99. Kurtz JE, Deplanque G, Duclos B et al. Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study. Gynecol Oncol 1998; 70: 414-417
100. Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 1983; 67: 997-1000
101. Bruckner HW, Wallach R, Cohen CJ et al. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1981; 12: 64-67
102. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246-1250
103. Barker GH, Wiltshaw E. Use of high-dose cis-dichlorodiammine platinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 1981; 88: 1192-1199
104. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393
105. Core ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Cynecol Oncol 1990; 36: 207-211
106. 2) treatment in ovarian carcinoma. Br J Cancer 1992; 66: 717-719
107. Reed E, Janik J, Bookman MA et al. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol 1993; 11: 2118-2126
108. Bolis G, Brusati M, Ferraris A et al. Carboplatin alone (C) vs. carboplatin + high-dose epirubicin (HDCE) + growth-factors (GF) in late recurrences ovarian cancer patients (PTS). Proc Am Soc Clin Oncol 1994; 13: 271
109. Conte PF, Gadducci A, Fioretti P, Bruzzone M, Brunetti I, Ragni N. Therapeutic experience of the North-West Oncology Group (GO-NO) on ovarian carcinoma. Eur J Gynaec Oncol 1994; 15: 313-318
110. Morgan RJ, Margolin K, Raschko J et al. Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J Clin Oncol 1995; 13: 2238-2246
111. Bolis G, Scarfone G, Luchinin L et al. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with cisplatin-or carboplatin-based regimens. Eur J Cancer 1994; 30A: 1764-1768
112. Dorval T, Soussain C, Beuzeboc P et al. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. J Infus Chemother 1996; 6: 47-49
113. Willemse PHB, Gietema JA, Mulder NH et al. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer 1993; 29A: 359-362
114. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-1753
115. Kohn EC, Sarosy G, Bicher A et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24
116. Chopra R, Ramesh N, Katiyar CK. A phase I-II study of intaxel, paclitaxel (PCL) obtained from himalayan yew tree (taxus baccata) in advanced ovarian cancer patients (PTS): an Indian experience. Proc Am Soc Clin Oncol 1995; 14: 280
117. Mendiola C, Garcia-Ribas I, Cubedo R et al. High response rate of taxol in platinum pretreated advanced ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 278
118. Omura GA, Brady MF, Delmore JE et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study. Proc Am Soc Clin Oncol 1996; 15: 280
119. Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Sem Oncol 1997; 24: S15-62-S15-67
120. Fennelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-192
121. Ezcurdia L, Jovtis SL, Mickiewicz E et al. Paclitaxel in platinum-resistant ovarian cancer patients. Sem Oncol 1997; 24 (suppl 15): S 15-53, S 15-56
122. Markman M, Rose PG, Jones E et al. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 1998; 16: 1849-1851
123. Pectasides D, Papadopoulou M, Varthalitis J et al. Paclitaxel incisplatin or carboplatin-pretreated ovarian cancer. Oncology 1998; 55: 228-234
124. Eckhardt S, Hernadi Z, Thurzo L et al. Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Oncology 1990; 47: 289-295
125. Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. Gynecol Oncol 1990; 36: 369-370
126. Hillcoat BL, Campbell JJ, Pepperell R, Quinn MA, Bishop JF, Day A. Phase Il trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985; 22: 162-166
127. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191-195
128. Marzola M, Zucchetti M, Colombo N et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993; 4: 517-519
129. Kühnle J, Hilfrich J. Chemotherapie des fortgeschrittenen Ovarialkarzinoms. Onkologie 1985; 8: 374-382
130. Yasumizu T, Kato J. Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus. J Obstet Gynaecol 1995; 21: 569-576
131. de Jong RS, Hofstra LS, Willemse PHB et al. Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1997; 66: 197-201
132. Garrow GC, Hainsworth JD, Johnson DH et al. Prolonged administration of oral etoposide in previously-treated epithelial ovarian cancer: a phase II trial. Proc Am Soc Clin Oncol 1992; 11: 236
133. Gore M, Rustin G, Calvert H et al. A multicentre, randomised, phase III study of topotecan (T) administered intravenously or orally for advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 1998; 17: 349A
134. Clarke-Pearson DL, Van Le L, Iveson T et al. A phase II study of oral topotecan as a single agent, second-line therapy, administered for five days in patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 363A
135. Eisenhauer E, Hoskins P, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 1997; 16: 249A
136. Dunton CJ, Neufeld J, Carlson JA et al. Secondary response of ovarian tumors to topotecan treatment. Gynecol Oncol 1998; 69: 258-259
137. Ghosh K, Murray KP, Chen MD et al. The role of extreme drug resistance assays on chemotherapeutic choice and response in ovarian carcinoma patients undergoing secondary cytoreductive surgery. Gynecol Oncol 1998; 70: 310
138. Veldhuis GJ, Willemse PHB, Beijnen JH et al. Paditaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Br J Cancer 1997; 75: 703-709
139. van der Burg MEL, de Wit R, Stoter G, Verweij J. Phase I study of weekly cisplatin (P) and weekly or 4-weekly taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC). Proc Am Soc Clin Oncol 1998; 17: 335A
140. Vincent P, Guastalla JP, Piedbois P et al. Taxol (T) + carboplatin (Cb) combination in pretreated ovarian cancer (OC): a randomized comparison of 2 carboplatin dose calculations (AUC vs. BSA). Proc Am Soc Clin Oncol 1998; 17: 1453
141. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16: 1494-1497
142. Coeffic D, Benhammouda A, Antoine EC et al. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results. Sem Oncol 1996; 23: 5-8
143. van der Burg MEL, Hoff AM, van Lent M, Rodenburg CJ, van Putten WLJ, Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur J Cancer 1991; 27: 248-250
144. Dittrich C, Baur M, Vavra N et al. Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients. Ann Oncol 1993; 4: 697-699
145. Chambers SK, Chambers JT, Kohorn EI, Schwartz PE et al. Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. Gynecol Oncol 1987; 27: 233-240
146. Dottino PR, Goodman HM, Kredentser D, Rosenberg M, Cohen CJ. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma. Gynecol Oncol 1987; 27: 350-356
147. Seltzer V, Vogl S, Kaplan B. Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cisdiamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 1985; 21: 167-176
148. Metzner M, Logue J, Wilkinson PM, James RD. Treatment of relapsed ovarian carcinoma with epirubicin, cis-platinum and 5-fluorouracil (ECF). Proc Am Soc Clin Oncol 1995; 14: 279
149. Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F. A phase Il study of carboplatin and cyclophosphamide in advanced ovari-an carcinoma. J Chemother 1993; 5: 47-51
150. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M, Wharton JT. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989; 73: 798-802
151. Chain JM, Collins C, Petrersdorf S et al. Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. Am J Obstet Gynecol 1996; 174: 1688-1694
152. Bruckner HW, Cohen CJ, Bhardwaj S, Feuer E, Chesser MR, Holland JF. Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer. Eur J Cancer Clin Oncol 1989; 23: 1273-1279
153. Reed E, Sarosy G, Kohn E et al. Phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary. Gynecol Oncol 1996; 61: 349-353
154. Olver IN, Davy M. A phase I study of paclitaxel and altretamine in ovarian cancer relapsing after cisplatin. Proc Am Soc Clin Oncol 1996; 15:297
155. Pucci F, Bella M, Salvagni S, Passalacqua R, Attolini C, Cocconi G. Paclitaxel and ifosfamide in heavily pretreated patients with advanced ovarian cancer. A pilot fase II study. Proc Am Soc Clin Oncol 1996; 15; 301
156. Poole CJ, Perren T, Hogberg T et al. Phase I study to investigate the optimal dose and schedule of gemcitabine (G) and paclitaxel (P) in combination in patients with previously treated epithelial ovarian cancer. Proc Am Soc Clin Oncol 1998; 17: 357A
157. Olver IN, Davy M, Birgeois C. Paclitaxel and altretamine for ovarian cancer relapsing following cisplatin. Proc Am Soc Clin Oncol 1998; 17: 317A
158. Olver I, Davy M, Webster L, Egorin M, Luftner D, Park SH. A phase I trial with pharmacokinetics of paclitaxel and altretamine for ovarian cancer relapsing following cisplatin. Ann Oncol 1998; 9: 68
159. Belinson JL, Pretorius RG, McLure M, Ashikaga T. Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies. Gynecol Oncol 1986; 23: 304-309
160. Sipila P, Kivinen S, Grohn P, Vesala J, Heinonen E. Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 1989; 34: 27-29
161. Trope C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemother Pharmacol 1990; 26: S45-S47
162. Bruzzone M, Campora E, Merlini L et al. Ifosfamide and etoposide salvage treatment in advanced ovarian cancer. J Chemother 1991; 3: 332-334
163. Alberts D, Garcia-Kendall D, Surwit A. Phase II trial of mitomycin C plus 5-FU in the treatment of drug-refractory ovarian cancer. Sem Oncol 1988; 15: 22-26
164. Barlow JJ, Lele SB. Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma. J Surg Oncol 1986; 32: 43-45
165. Redman C, Lawton F, Stuart N et al. Phase II study of combination 4′-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 1989; 23: 51-53
166. Litam PP, Green JB, Capen C. Mitomycin-C-plus a 4 day continuous infusion of 5-fluorouracil as salvage regimen after platinum-based therapy in women with advanced ovarian cancer and related gynecologic malignancies. Proc Am Soc Clin Oncol 1996; 15: 288
167. Di Leo A, Bajetta E, Biganzoli L et al. An I.T.M.O. Group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. Eur J Cancer 1995; 31: 2248-2254
168. Marzola M, Parma G, Bonazzi C et al. Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer. Ann Oncol 1996; 7:419-421
169. Nardi M, Delia Giulia M, Pollera CF et al. A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 1996; 38: 298-301
170. Fleming GF, Waggoner SE, Rotmensch J, Skoog LA, Langhauser C. Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer. Gynecol Oncol 1997; 65: 42-45
171. Zanetta G, Lo Monico S, Gabriele A, Miceli D, Mangioni C Che-motherapie with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment. Eur J Cancer 1996; 32A: 178-179
172. Linasmita V, Wilailak S, Srispundit S, Tangtrakul S, Bullangpoti S, Israngura N. Ifosfamide/mesna plus adriamycin as salvage therapy of advanced epithelial ovarian cancer, Int J Gynecol Cancer 1997; 7: 388-391
173. Herben VMM, ten Bokkel Huinink WW, Dubbelmann AC et al. Phase 1 and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997; 76: 1500-1508
174. Guastalla JP, Ferrero JM, Benbunan JL et al. Topotecan (T) followed by etoposide (E) in pretreated ovarian cancer (OC) patients (pts): a CINECO phase II study. Ann Oncol 1998; 9: 67
175. Gwyther SJ, Gore ME, ten Bokkel Huinink W et al. Results of independent radiological review of over 400 patients with advanced ovarian cancer treated with topotecan (Hycamtin). Proc Am Soc Clin Oncol 1997; 16: 1255
176. Aghajanian C, Gogas H, Fennelly D et al. Second-line paclitaxel therapy in patients with ovarian cancer previously treated with a taxane. Proc Am Soc Clin Oncol 1996; 15: 69
177. Schink JC, Narris LS, Grosen EA, Bailey HH. Altretamine (hexalen) an effective salvage chemotherapy after paclitaxel (taxol) in women with recurrent platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275
178. Markman M. Ifosfamide in the treatment of ovarian cancer. Sem Oncol 1996; 23: 47-49
179. Markman M, Kennedy A, Sutton G et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol 1998; 70: 272-274
180. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-993
181. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93
182. Sugiyama T, Nishida T, Ookura N et al. Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer? Proc Am Soc Clin Oncol 1997; 16: 378A
183. de Palo GM, De Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 1975; 141: 899-902
184. Gordon A, Carmichael J, Malfetano J et al. Final analysis of a pha-se III randomized study of Topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma (OC): International Topotecan Study Group. Proc Am Soc Clin Oncol 1998; 17: 1374
185. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL et al. Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma. Cancer 1984; 53: 1467-1472
186. Pater JL, Carmichael JA, Krepart GV et al. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 1987; 71: 277-281
187. Krafft W. Die Effektivität von Platin als Mono-und Kombinationstherapie bei primär resistentem oder rezidivierendem Ovarialkarzinom. Zentralbl Gynäkol 1989; 14: 938-946
188. Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer 1980; 45: 2529-2542
189. Eisenhauer EA, Vermerken JB, van Glabbeke M. Predictors of re-sponse to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-968
190. Hoskins P, Tu D, James K, Koski B. Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis-derived model with test and validation groups. Gynecol Oncol 1998; 70: 224-230
191. Williams CJ. Tamoxifen in relapsed ovarian cancer: A systematic review. Int J Gynecol Cancer 1998; 8: 89-94
192. Kavanagh JJ, Roberts W, Townsend P, Hewitt S, Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989; 7: 115-118
193. Miller DS, Brady MF, Barrett RJ. A phase II Trial of leuprolide ace-tate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1992; 15: 125-128
194. Bruckner HW, Motwani BT. Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol 1989; 161: 1216-1218
195. Kurbacher CM, Bruckner HW, Mallmann P, Krebs D. Mitoxantron kombiniert mit Paclitaxel beim platinrefraktären Ovarialkarzinomrezidiv: Präklinische und erste klinische Resultate. Arch Gynecol Obstet 1996; 258: S19
196. Eltabbakh GH, Piver MS, Hempling RE et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 1998; 70: 392-397
197. Morgan RJ, Speyer J, Doroshow JH et al. Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol 1995; 58: 79-85
198. Long III HJ, Nelimark RA, Su JQ et al. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma. Gynecol Oncol 1994; 54: 180-183
199. de Craeff A, van Hoef MEHM, Tjia P, Heintz APM, Neijt JP. Continuous infusion of 5-fluorouracil in ovarian cancer patients refractory to cisplatin and carboplatin. Ann Oncol 1991; 2: 691-692
200. van Oosterom AT, ten Bokkel Huinink W, van der Burg MEL, Vermorken JB, Willemse PHB, Neijt JP. Phase II clinical trial of doxyfluridine in patients with advanced ovarian cancer. Eur J Cancer 1991; 27: 747-749
201. Louvet C, de Gramont A, Demuynck B et al. Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: a phase II study. Ann Oncol 1992; 3: 657-658
202. Reed E, Jacob J, Ozols RF, Young RC, Allegra C. 5-fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma. Gynecol Oncol 1992; 46: 326-329
203. Look KY, Muss HB, Blessing JA, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. Clin Oncol 1995; 18: 19-22
204. Kamphuis JT, Huider MC, Ras GJ et al. High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer. Cancer Chemother Pharmacol 1995; 37: 190-192
205. Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/ mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995; 56: 75-78
206. Markman M, Hakes T, Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243-248
207. Gropp M, Meier W, Hepp H. Treosulfan als effiziente Second-line-Therapie beim Ovarialkarzinom. Geburtsh u Frauenheilk 1997; 57: 356-360
208. Harstrick A, Wilke H, Eberhard W et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153-156
209. Keldsen N, Madsen EL, Havsteen H et al. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study, Gynecol Oncol 1998; 69: 100-102
210. Hauge MD, Long HJ, Hartmann LC, Edmonson JH, Webb MJ, Su J. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest New Drugs 1992; 10: 299-301
211. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47: 282-286
212. Moore DH, Valea F, Grumpier LS, Fowler WC. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 1993; 51: 109-112
213. Vermorken JB, Kobierska A, van der Burg MEL et al. High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. Eur J Gynaec Oncol 1995; 16: 433-438
214. Gaducci A, Brunetti I, Muttini MP et al. Epidoxorubicin and Ionidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 1994; 30A: 1432-1435
215. Havsteen H, Bertelsen K, Gadeberg CC et al. A phase 2 study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer. Gynecol Oncol 1996; 63: 210-215
216. Safra T, Jeffers S, Groshen S et al. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from three consecutive phase I/II studies. Proc Am Soc Clin Oncol 1997; 16: 349A
217. Garcia A, Muggia FM. Activity of anthracyclines in refractory ovarian cancer: recent experience and review. Cancer Invest 1997; 15: 329-334
218. Pelaez I, Lacave AJ, Palacio I et al. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur J Cancer 1996; 32A: 899-900
219. Locatelli MC, D'Antona A, Vinci M, Carcione R, Pasquinucci C. Luporini G. Trattamento di 2 linea del carcinoma ovarico avanzato (CAO) con epirubicina (EDR). Tumori 1997; 76: 138
220. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2'.2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533
221. Neijt JP, Kaufmann M, Bauknecht T et al. Gemcitabine in pretreated ovarian cancer. Ann Oncol 1996; 7: 70
222. George MJ, Heron JF, Kerbrat P et al. Navelbine in advanced ovarian epithelial cancer: a study of the French Oncology Centers. Sem Oncol 1989; 16: 30-32
223. Bajetta E, Di Leo A, Biganzoli L et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14: 2546-2551
224. Gershenson DM, Burke TW, Morris M et al. A phase I study of a daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol 1998; 70: 404-409
225. Vergote IB, Trope CG. Ifosfamide-etoposide therapy in platin-resistant ovarian carcinoma. Proc Am Soc Clin Oncol 1995; 14: 273
226. Look KY, Blessing JA, Muss HB, DeGeest K. 5-fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma. Am J Clin Oncol 1992; 15: 494-496
227. Burnett AF, Barter JF, Potkul RK, Barnes WA. Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer. Am J Clin Oncol 1994; 17: 490-493
228. Prefontaine M, Donovan JT, Powell JL, Buley L. Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin. Gynecol Oncol 1996; 61: 249-252
229. Hoffmann L, Koppermann S, Müllerleile U. Treosulfan in the treatment of ovarian carcinoma. Onkologie 1991; 14: 8-9
230. Kramer D, Golz N, Glaser D, Mast H. Treosulfan als Second-Line-Therapie beim fortgeschrittenen Ovarialkarzinom. Arch Gynecol Obstet 1991; 250: 195-196
231. Friedlander M, De Gramont A, Millward MJ et al. Activity of gemcitabine in stage 3 or 4 ovarian cancer: patients previously treated with cisplatin (CP)-containing regimens. Eur J Cancer 1997; 33: 5121-5122
232. Coleman R, Towlson K, Wiltshaw E et al. Epirubicin for pretreated advanced ovarian cancer. Eur J Cancer 1990; 26: 850-851
233. Ozols RF, Cunnion RE, Klecker RW et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641-647
234. Gordon AN, HainsworthJ, Moore M et al. Doxil (doxorubicin HCl liposome injection) in the treatment of patients with refractory advanced ovarian carcinoma - results of an interim analysis. Proc Am Soc ClinOncol 1998; 17: 1345
235. Willemse PHB, van der Burg MEL, van der Gaast A et al. Ifosfamide given as 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. Cancer Chemother Pharmacol 1990; 26: 51-54
236. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1672-1676
237. Rosen GF, Lurain JR, Newton M. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gynecol Oncol 1987; 27: 173-179
238. Stehman FB, Ehrlich CE, Callangan MF. Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Gynecol Oncol 1984; 17: 189-195
239. Maneta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997; 66: 20-26
240. Moore DH, Fowler Jr WC, Jones CP, Grumpier LS. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. Am J Obstet Gynecol 1991; 165: 573-576
241. Rustin GJS, Nelstorp AE, Crawford M et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evolution of defining response by serum CA 125. J Clin Oncol 1997; 15: 172-176
242. Burger RA, Burman S, White R, DiSaia PJ. Phase II trial of navelbine in advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1996; 15: 286
243. Rothenberg ML, Ostchega Y, Steinberg SM et al. High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst 1988; 80: 1488-1492